FierceBiotech

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...
The Trentonian

Janssen Submits New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

RARITAN, N.J., June 23, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug ...
pharmaphorum

Bayer left playing catch-up with BMS after Xarelto failure

Bayer has said a failed trial for a potential new use of anticoagulant Xarelto will not affect forecast peak sales of $5 billion – although it will not help it gain ground on Bristol-Myers Squibb’s ...
FierceBiotech

Bayer's Xarelto Approved in Canada

First approval for Bayer's new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct ...
TCTMD

Rivaroxaban May Help Dissolve Left Atrial Thrombus in Patients With A-fib

Providing validation to what many physicians are already doing, a new study suggests that non-vitamin K antagonist oral anticoagulants (NOACs)—rivaroxaban, in particular—are effective alternatives to ...
FiercePharma

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...